Crinetics Pharmaceuticals (CRNX) Earnings Date, Estimates & Call Transcripts $53.14 +0.37 (+0.70%) (As of 10/4/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 5EstimatedActual EPS (Aug. 8) -$0.94 Missed By -$0.08 Consensus EPS (Aug. 8) -$0.86 Conference Call TranscriptConference Call AudioEarnings Press Release Get Crinetics Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for CRNX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCRNX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CRNX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust. Crinetics Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.84)($0.68)($0.76)Q2 20242($0.86)($0.71)($0.79)Q3 20242($0.90)($0.74)($0.82)Q4 20242($0.90)($0.77)($0.84)FY 20248($3.50)($2.90)($3.20)Q3 20251($1.01)($1.01)($1.01)Q4 20251($1.02)($1.02)($1.02)CRNX Earnings Date and InformationCrinetics Pharmaceuticals last released its earnings data on August 8th, 2024. The reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.08. The company earned $0.40 million during the quarter, compared to analyst estimates of $0.47 million. Its revenue was down 59.6% compared to the same quarter last year. Crinetics Pharmaceuticals has generated ($3.78) earnings per share over the last year (($3.78) diluted earnings per share). Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($3.86) per share. Crinetics Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off prior year's report dates.Read More Crinetics Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/5/2024(Estimated)------- 8/8/2024Q2 2024($0.86)($0.94)($0.08)($0.94)$0.47 million$0.40 million 5/9/2024Q1 2024($0.84)($0.93)($0.09)($0.93)$0.20 million$0.64 million 2/28/2024Q4 2023($0.89)($0.90)($0.01)($0.90)$0.20 million- 11/7/2023Q3 2023($0.89)($1.01)($0.12)($1.01)-$0.35 million 8/8/2023Q2 2023($0.85)($0.94)($0.09)($0.94)$5.00 million$0.99 million5/4/2023Q1 2023($0.82)($0.85)($0.03)($0.85)$0.63 million$2.68 million Get the Latest News and Ratings for CRNX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/2023Q4 2022($0.82)($0.84)($0.02)($0.84)$0.75 million$0.71 million11/14/2022Q3 2022($0.78)($0.78)-($0.78)$1.00 million$0.46 million8/12/2022Q2 2022($0.62)($0.81)($0.19)($0.81)$1.80 million$0.44 million5/12/2022Q1 2022($0.56)($0.73)($0.17)($0.73)-$3.13 million3/30/2022Q4 2021($0.57)($0.68)($0.11)($0.68)-$1.08 million11/5/2021Q3 2021($0.72)($0.73)($0.01)($0.73)-- 8/9/2021Q2 2021($0.61)($0.70)($0.09)($0.70)--5/6/2021Q1 2021($0.66)($0.69)($0.03)($0.69)-- 3/29/2021Q4 2020($0.58)($0.66)($0.08)($0.66)-- 11/11/2020Q3 2020($0.53)($0.56)($0.03)($0.56)-- 8/7/2020Q2 2020($0.55)($0.53)+$0.02($0.53)--5/8/2020Q1 2020($0.63)($0.71)($0.08)($0.71)-$0.07 million3/9/2020Q4 2019($0.68)($0.60)+$0.08($0.60)$0.30 million$0.32 million11/12/2019Q3 2019($0.5680)($0.60)($0.0320)($0.60)$0.33 million$0.51 million Crinetics Pharmaceuticals Earnings - Frequently Asked Questions When is Crinetics Pharmaceuticals's earnings date? Crinetics Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off last year's report dates. Learn more on CRNX's earnings history. Did Crinetics Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Crinetics Pharmaceuticals (NASDAQ:CRNX) missed the analysts' consensus estimate of ($0.86) by $0.08 with a reported earnings per share (EPS) of ($0.94). Learn more on analysts' earnings estimate vs. CRNX's actual earnings. How can I listen to Crinetics Pharmaceuticals's earnings conference call? The conference call for Crinetics Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Crinetics Pharmaceuticals's conference call transcript? The conference call transcript for Crinetics Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Crinetics Pharmaceuticals generate each year? Crinetics Pharmaceuticals (NASDAQ:CRNX) has a recorded annual revenue of $1.39 million. How much profit does Crinetics Pharmaceuticals generate each year? Crinetics Pharmaceuticals (NASDAQ:CRNX) has a recorded net income of -$214.53 million. CRNX has generated -$3.78 earnings per share over the last four quarters. What is Crinetics Pharmaceuticals's EPS forecast for next year? Crinetics Pharmaceuticals's earnings are expected to decrease from ($3.72) per share to ($3.86) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Ionis Pharmaceuticals Earnings Avadel Pharmaceuticals Earnings Bicycle Therapeutics Earnings Viatris Earnings Dr. Reddy's Laboratories Earnings Vaxcyte Earnings Sarepta Therapeutics Earnings Catalent Earnings Qiagen Earnings Roivant Sciences Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Nike’s Post-Earnings Drop Presents a Buying OpportunityMicron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season? This page (NASDAQ:CRNX) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.